Skip to main content
search
Conference

SOT Annual Meeting and ToxExpo 2025

Conference: SOT Annual Meeting and ToxExpo 2025

Date: March 16-20, 2025

Location: Orlando, FL

Booth: #1147

Where to hear Certara insights and Expertise

Tuesday, March 18, 2025 | 8:40am - 9:15am | Room: W203A
Are Metabolites of Concern? Suggestion of a Tiered Testing and Assessment Approach

Presenters: Barira Islam, Sr. Research Scientist

Wednesday, March 19, 2025 | 1:45pm-2:45pm | Room: W208B
Early de-risking of small molecule pipelines using in silico tools

Presenters: Will Redfern

Demo Schedule

Monday, March 17 (during afternoon refreshment break)

  • Secondary Intelligence (Off-target risk prediction software) 2:30pm-3:00pm (Will Redfern)
  • libra (AI-powered DILI prediction software) 3:00pm-3:30pm (Barira Islam)

Tuesday, March 18 (during Smoothie Schmooze)

  • Simcyp Simulator (Modeling and Simulation Platform) 3:00pm-3:30pm (Himanshu Mishra)
  • libra (AI-powered DILI prediction software) 3:30pm-4pm (Will Redfern)

Wednesday, March 19 (during afternoon refreshment break)

  • Secondary Intelligence (Off-target risk prediction software) 2:30pm-3:00pm (Barira Islam)
  • libra (AI-powered DILI prediction software) 3:00pm-3:30pm (Will Redfern)

Book your personalized SEND Explorer demo now for a chance to win Apple AirPods

Contact us

Certara’s Toxicology Solutions

Certara offers advanced toxicology solutions to predict, assess, and mitigate safety risks in drug development. Using technologies like Quantitative Systems Toxicology (QST) and physiologically based pharmacokinetic (PBPK) modeling, we help foresee toxicological outcomes such as hepatotoxicity, cardiotoxicity, and immunotoxicity.

Key Offerings:

  1. Translational Modeling: Bridges preclinical data to human predictions.
  2. Toxicokinetic (TK) Analysis: Establishes safety margins.
  3. Complex Therapies: Specializes in biologics and gene therapies.
  4. Virtual Tissue Models: Evaluates off-target effects, drug-drug interactions (DDIs), and immunogenicity risks.
  5. Early Development: Specialized early development services designed to optimize this critical phase of drug development. Our approach combines cutting-edge science with extensive experience to provide you with a clear, strategic roadmap. From preclinical testing to early clinical trials, owe help streamline the process and address potential issues before they become major hurdles.

Featured Tools:

  1. SEND Explorer: A web-based application for managing nonclinical study data, offering advanced capabilities for viewing, summarizing, and visualizing data in the SEND format to aid decision-making.
  2. Secondary Intelligence: Predicts off-target adverse events using screening data, helping to identify potential safety risks and prioritize compounds based on safety profiles.

We support all stages of drug development and assist with regulatory submissions (INDs, NDAs, BLAs). Our consulting and training services help navigate regulatory challenges and optimize safety studies.

Join Us at SOT! Explore our vendor-hosted presentations and experience live demos of SEND Explorer and Secondary Intelligence. Stay tuned for updates!

 

Additional Resources

You May Also Like

DIA Europe 2025
DIA Europe 2025Conference

DIA Europe 2025

AMCP 2025
AMCP 2025Conference

AMCP 2025

BioIT World 2025
BioIT World 2025Conference

BioIT World 2025